Antiviral efficacy and serum interferon-γ and interleukin-10 level changes in patients with chronic hepatitis C with genotype 1b infection
Objective The aim of this study was to observe the antiviral efficacy and serum interferon-γ(IFN-γ)and interleukin-10(IL)-10)level changes in patients with chronic hepatitis C(CHC)with genotype 1b infection.Methods 58 patients with CHC and genotype 1b infection were recruited in our hospital between May 2020 and February 2023,and the antiviral regimen by sorfosbuvir/daratavir was given in 30 patients in the observation group and by peginterferon α-2a and ribavirin combination was given in 28 patients in the control.The treatment lasted for 24 weeks in the two groups.Serum IFN-γ and IL-10 levels were measured by ELISA.Results At the end of the antiviral treatment,the white blood cell count,platelet count and hemoglobin concentration in the observation group were(5.5±1.2)×10 9/L,(116.2±19.5)x 109/L and(121.5±19.7)g/L,all significantly higher than[(4.6±1.1)×10 9/L,(94.0±18.5)×10 9/L and(104.7±16.8)g/L,respectively,P＜0.05]in the control;serum ALT and AST levels in the observation group were(36.0±5.0)U/L and(38.2±5.5)U/L,both significantly lower than[(47.5±5.8)U/L and(51.9±6.3)U/L,P＜0.05]in the control;serum CRP and IL-10 levels in the observation group were(13.4±1.8)ng/L and(36.5±14.6)pg/mL,both significantly lower than[(16.7±2.2)ng/L and(64.0±28.2)pg/mL,P＜0.05],while serum IFN-γ level was(19.2±2.0)pg/mL,significantly higher than[(10.4±2.2)pg/mL,P＜0.05]in the control;the rapid virological response,early virological response,end-of-treatment response and sustained virological response in the observation group were 73.3％,90.0％,100.0％and 96.7％,all significantly higher than 42.8％,53.6％,71.4％and 60.7％(P＜0.05)in the control group;at the end of four-week treatment,serum IFN-γ level in 46 responders was(23.5±4.7)pg/mL,much higher than[(8.5±1.7)pg/mL,P＜0.05],while serum IL-10 level was(29.0±13.2)pg/mL,much lower than[(84.5±30.1)pg/mL,P＜0.05]in twelve non-responders.Conclusion The application of sorfosbuvir and daratavir in the treatment of patients with genotype 1 b CHC has a good efficacy,which might be be related to the inhibition of viral replication and the successful induction of antiviral immunization.
万方数据
维普
